HCPCS Code J0896: Injection, Luspatercept-aamt, 0.25 mg

Learn about the HCPCS code J0896 for "Injection, luspatercept-aamt, 0.25 mg" through this short guide.

## **What is the HCPCS code J0896 for?** The HCPCS code J0896 is meant to designate the injection of luspatercept-aamt, specifically a 0.25 mg dose. Luspatercept-aamt injections, sometimes referred to by the brand name Reblozyl injections, are a type of injected medication/erythroid maturation agent used to treat patients with a kind of anemia associated with beta-thalassemia, a kind of inherited blood disorder characterized by the body's inability to produce enough hemoglobin. These patients require regular red blood cell unit transfusions. It's also used to treat patients with very low to intermediate risk myelodysplastic syndromes (MDS) when previous erythropoiesis-stimulating agent (ESA) therapy has failed. What this drug does is to help erythroid cells (immature red blood cells) mature and become working red blood cells, and in turn, make them produce a bigger amount of hemoglobin. More hemoglobin means that the cells can carry more oxygen, which improves the anemia of the patient. Please note that this subcutaneous injection is meant to treat patients. It is not a diagnostic injection. It's also only meant to be used on adult patients. It is currently unknown what side effects this will have on children, so please don't use it on them. It's also not a form of chemotherapy administration.

## **Documentation requirements for J0896** As with any HCPCS code, it's important to have sufficient documentation before filing a claim for any code. Here are some of the things you need for J0896: - The full name of the patient - The name and address of the facility where the injection was administered - The full name and credentials of the healthcare professionals who handled the patient - The date and time of the drug administration by subcutaneous injection - Patient records showing they have anemia with beta thalassemia, or anemia of myelodysplastic syndrome or myelodysplastic/myeloproliferative neoplasm - Supportive clinical data, such as hemoglobin values, transfusion history, and scoring systems (e.g., IPSS-R or WPSS for MDS risk stratification) - Documented transfusion dependence or ESA failure (e.g. treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks) - Luspatercept-aamt/Reblozyl prescribing information - Blood test results - Imaging test results showing locations and sizes of tumors (if any) - The exact dosage and route

## **Billing requirements for J0896** Besides the documentation requirements above, please make sure to take note of or have the following: - 1 unit = 0.25 mg - Any relevant ICD codes related to the patient's condition - Use either of two modifiers: JW if there's unused medication in a vial (wastage), or JZ if there's no unused medication - Use CPT code 96372 since this is a subcutaneous injection - Be aware of payer-specific authorization timelines (e.g., initial vs. continuation therapy)—commonly up to 12 months—with updated approval contingent on response (e.g., reduced transfusion burden, improved hemoglobin) Please familiarize yourself with the necessary CMS/Medicaid services/related guidelines and policy articles so you can follow correct coding practices and avoid claim rejections.

## **Other similar codes** - **J0897** - Injection, denosumab, 1 mg - **J0898** - Injection, argatroban (auromedics), not therapeutically equivalent to j0883, 1 mg (for non-esrd use) - **J0899** - Injection, argatroban (auromedics), not therapeutically equivalent to j0884, 1 mg (for esrd on dialysis) - **J0911** - Instillation, taurolidine 1.35 mg and heparin sodium 100 units (central venous catheter lock for adult patients receiving chronic hemodialysis)

Frequently asked questions

They need to inform their healthcare professionals about any medicine they've been taking. This is so they can determine if there will be negative drug interactions or not.

The common side effects include feeling tired, dizzy, and nauseous. It's possible for patients to feel joint pain and/or stomach pain. They might start coughing, have trouble breathing, or even have high blood pressure.

Blood clots in the arteries, veins, brain, and lungs. This is bad and must be treated as soon as possible.